Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

STTK vs CASI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

STTK Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–1 Matrix Metrics)

STTK Overall Winner 6-Pillar Tally: STTK 3 – 2 CASI (1 Tie) Matrix Metrics: STTK 7 – 1 CASI

As of Nov 20, 2026, Shattuck Labs, Inc. (STTK) is the stronger overall head-to-head candidate over CASI Pharmaceuticals, Inc. (CASI) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). STTK carries a Unified Composite Score of 61.7/100 (BUY) at $4.46 (N/M Forward P/E, 0.0% operating margin), whereas CASI carries 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin).

  • Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.5); meanwhile CASI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About STTK vs CASI
STTK NASDAQ Head-to-Head Winner
Shattuck Labs, Inc. Common Stock
Pharmaceutical Preparations
$4.46
-1.98% 1D
Market Cap $459.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.41β · 68% Vol
Unified Composite Score
61.7 / 100 BUY
Tech 78.0 Fund 69.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.1%), weak momentum, RSI 35
RSI-14: 35.5 · SMA20: $5.03 · SMA50: $5.61
CASI NASDAQ
CASI Pharmaceuticals, Inc. Ordinary Shares
Pharmaceutical Preparations
$0.21
-74.06% 1D
Market Cap $12.4M
TTM Revenue $27M
Forward P/E N/M
Beta / 30D Vol 0.95β · 240% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 40.0 Fund 44.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.5%), weak momentum, RSI 18
RSI-14: 18.4 · SMA20: $0.84 · SMA50: $0.88

6-Pillar Scorecard Institutional Category Breakdown (STTK 3 – 2 CASI)

Columns: Metric · STTK · CASI
1. Valuation Multiples CASI
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.5x
2. Growth & Scale CASI
Revenue Growth (YoY) -66.6% -60.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $27M
Market Cap $459.3M $12.4M
3. Profitability & Quality STTK
Gross Margin N/A 35.8%
Operating Margin 0.0% -333.1%
Net Profit Margin 0.0% -184.0%
Return on Equity (ROE) -47.2% -1094.5%
4. Balance Sheet & Cash Flow STTK
Cash Generation (TTM) -$50M -$42M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $59M Net Cash -1094.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning STTK
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 72.4% (10th %ile) N/A (N/A)
Put/Call OI Skew 4.66x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: STTK (7) vs CASI (1)
Institutional Metric STTK CASI Criterion Row Edge
Market Capitalization
Scale
$459.3M $12.4M Larger Scale STTK
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-66.6% -60.5% Higher Growth CASI
Operating Margin (TTM)
Profitability
0.0% -333.1% Higher Margin STTK
Net Profit Margin
Profitability
0.0% -184.0% Higher Margin STTK
Return on Equity (ROE)
Capital Efficiency
-47.2% -1094.5% Higher ROE STTK
52-Week Range Position
Momentum
40% ($2–$8) 0% ($0–$3) Stronger Trend STTK
Beta / 30D Volatility
Risk Regime
1.41β · 68% Vol 0.95β · 240% Vol Lower Realized Risk STTK
Unified Institutional Score
Composite Signal
61.7 / 100 (BUY) 44.7 / 100 (HOLD) Higher Composite STTK
Trailing 12M Revenue (USD)
Operating Scale
N/A $27M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 35.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$50M ($59M Net Cash) -$42M EBITDA (-1094.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon STTK +78.58 pp
STTK: -0.25% · CASI: -78.83%
3M Horizon STTK +182.64 pp
STTK: +99.51% · CASI: -83.13%
6M Horizon STTK +189.34 pp
STTK: +106.63% · CASI: -82.71%
1Y Horizon STTK +189.34 pp
STTK: +106.63% · CASI: -82.71%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STTK vs CASI. Trailing 12-month operating profitability (STTK 0.0% vs CASI -333.1%) and valuation multiples (STTK N/M vs CASI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

STTK ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-47.2% · N/M
CASI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$27M
Gross Margin35.8%
Op. Margin-333.1%
ROE / Fwd P/E-1094.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
STTK BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 72.4%
IV Percentile 10th %ile
Put/Call OI Skew 4.66x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact STTK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CASI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CASI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
STTK Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $459.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CASI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $12.4M market capitalization and -333.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ STTK vs CASI Key Questions & Quantitative Answers

As of Nov 20, 2026, Shattuck Labs, Inc. (STTK) is the stronger overall head-to-head candidate over CASI Pharmaceuticals, Inc. (CASI) in the Tradestie Institutional Equity Comparison Engine, winning 7–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). STTK carries a Unified Composite Score of 61.7/100 (BUY) at $4.46 (N/M Forward P/E, 0.0% operating margin), whereas CASI carries 44.7/100 (HOLD) at $0.21 (N/M Forward P/E, -333.1% operating margin). Technical & Structure Timing Caution: STTK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.5); meanwhile CASI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CASI leads the Growth & Scale pillar: STTK posts -66.6% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CASI at -60.5% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (35.8% gross margin, -333.1% operating margin). On trailing 12-month operating scale, STTK generates N/A in USD-normalized revenue versus $27M for CASI. In operating R&D and SG&A reinvestment, STTK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CASI.

CASI screens cheaper on headline valuation multiples. STTK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CASI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against STTK (-47.2% ROE) versus CASI (-1094.5% ROE) capital efficiency.

In options market volatility and institutional positioning, STTK carries 72.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 4.66x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.41β · 68% Vol realized risk). By comparison, CASI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.95β · 240% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.